Media Coverage

Media Coverage

Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.

BioSpace logo image
Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression
Read
Thepharmaletter logo image
VistaGen CEO notes broad market potential of ketamine-like AV-101
Read
San Francisco Business Times logo image
Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Read
PharmaTimes logo image
Company focus: VistaGen
Read
DDNews1 logo image
VistaGen acquires worldwide license of phase 3-ready CNS drug
Read
FierceBiotech logo image
VistaGen nabs phase 3-ready social anxiety drug from Pherin
Read
Business Insider logo image
Stanford researchers are figuring out how ketamine fights depression — and why the drug has been called 'the most important discovery in half a century'
Read
CNBC logo image
Ketamine is emerging as a popular treatment for depression. New research suggests the drug acts like an opioid
Read
Inc. logo image
24 Simple Ideas on How to Change Your Habits and Get More Done Today
Read